Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026

Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025

Same author

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances·2025

Same author

Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia.

bioRxiv : the preprint server for biology·2025

Same author

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockade.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Sep 26, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis.

Rongqing Pan¹, Jeremy Ryan¹, Deng Pan²

¹Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.

|April 21, 2022

Summary

Natural killer (NK) cells are crucial for cancer immunotherapy, but their effectiveness is limited. This study reveals that enhancing the mitochondrial apoptosis pathway in cancer cells boosts NK cell killing efficacy, offering a new therapeutic strategy.

Keywords:

BCL-2 BH3 mimetics BH3 profiling MCL-1 T cells immunotherapy mitochondrial apoptosis natural killer synergy venetoclax

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Published on: December 26, 2019

Related Experiment Videos

Last Updated: Sep 26, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry

Published on: December 26, 2019

Area of Science:

Immunology
Cancer Biology
Cell Death Pathways

Background:

Natural killer (NK) cell-based immunotherapy shows promise for cancer treatment but faces limitations in clinical efficacy.
Augmenting the cytotoxic capacity of NK cells is critical for improving immunotherapy outcomes.
The mitochondrial apoptosis (mtApoptosis) pathway's role in NK cell-mediated cytotoxicity requires further elucidation.

Purpose of the Study:

To investigate the essential role of the mtApoptosis pathway in NK cell-mediated cancer cell killing.
To explore how NK cells prime cancer cells for mtApoptosis and how this affects susceptibility.
To develop a rational strategy for enhancing NK cell-based cancer immunotherapy.

Main Methods:

Investigated the necessity of the mtApoptosis pathway for NK cell cytotoxicity at various effector-to-target ratios.
Assessed the ability of NK cells to prime cancer cells for mtApoptosis.
Utilized BH3 profiling to predict optimal BH3 mimetics for combination therapy.
Evaluated the synergistic effects of combining BH3 mimetics with NK cells in vitro and in vivo.

Main Results:

The mtApoptosis pathway is essential for efficient NK cell killing, particularly at physiological effector-to-target ratios.
NK cells can induce mitochondrial priming in cancer cells, influencing their susceptibility to NK-mediated killing.
Pre-activated NK cells exhibit resistance to BH3 mimetics.
Combining BH3 mimetics with NK cells demonstrates synergistic cancer cell killing in vitro and tumor growth suppression in vivo.

Conclusions:

The mtApoptosis pathway is a key determinant of NK cell efficacy in cancer immunotherapy.
Targeting mitochondrial priming and combining BH3 mimetics with NK cells offers a potent strategy to enhance cancer immunotherapy.
This precision approach, guided by BH3 profiling, can improve NK cell-based treatments and may be adaptable for T cell-based immunotherapies.